Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Locatelli, 1997, Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group, Kidney International - Supplement, 52, S63
Maschio G Alberti D Janin G Locatelli F Mann J Motolese M The use of benazepril in the treatment of progressive renal disease [abstract] 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 65
Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group, New England Journal of Medicine, 334, 939, 10.1056/NEJM199604113341502
Maschio, 1999, Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group, Journal of Cardiovascular Pharmacology, 33, S16, 10.1097/00005344-199900001-00004
Matsuda, 2003, Differing anti-proteinuric action of candesartan and losartan in chronic renal disease, Hypertension Research: Official Journal of the Japanese Society of Hypertension, 26, 875, 10.1291/hypres.26.875
Matsuda, 2003, Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease, Journal of Human Hypertension, 17, 271, 10.1038/sj.jhh.1001543
Solomon, 2006, Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial, Circulation, 114, 26, 10.1161/CIRCULATIONAHA.105.592733
Remuzzi, 1991, A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies, Journal of Nephrology, 4, 193
Ruggenenti, 1999, Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria, Lancet, 354, 359, 10.1016/S0140-6736(98)10363-X
Ruggenenti, 1997, The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract], Journal of the American Society of Nephrology, 8, 147A
Ruggenenti, 2001, ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy, Journal of the American Society of Nephrology, 12, 2832, 10.1681/ASN.V12122832
Kusek, 1996, Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, Controlled Clinical Trials, 17, 40S, 10.1016/S0197-2456(97)82681-5
Acone, 2003, Long term effects of combined therapy with ace-inhibitor and angiotensin ii receptor antagonist on non-diabetic nephropathies [abstract], Nephrology Dialysis Transplantation, 18, 365
Appel, 2008, Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans, Archives of Internal Medicine, 168, 832, 10.1001/archinte.168.8.832
Aranda, 2005, Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies, American Journal of Kidney Diseases, 46, 1074, 10.1053/j.ajkd.2005.08.034
Bakris, 1999, Differential effects of valsartan (v) and lisinopril (l) on potassium [k+] homeostasis in hypertensive patients with nephropathy [abstract], Journal of the American Society of Nephrology, 10, 68A
Bakris, 2000, ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group, Kidney International, 58, 2084, 10.1111/j.1523-1755.2000.00381.x
Bakris, 2000, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?, Archives of Internal Medicine, 160, 685, 10.1001/archinte.160.5.685
Balamuthusamy, 2008, Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis, American Heart Journal, 155, 791, 10.1016/j.ahj.2008.01.031
Bianchi, 1992, Effect of converting enzyme inhibitors (CEI) on renal function in hypertensive patients with chronic renal failure (CRF) [abstract], Journal of the American Society of Nephrology, 3, 280
Bonner, 1993, Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy, Arzneimittel Forschung, 43, 852
Campbell, 2003, Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies, Kidney International, 63, 1094, 10.1046/j.1523-1755.2003.00832.x
Carlsen, 1989, Efficacy and safety of cilazapril in hypertensive patients with moderate to severe renal impairment, American Journal of Medicine, 87, 79S, 10.1016/S0002-9343(89)80936-2
Casas, 2005, Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis, Lancet, 366, 2026, 10.1016/S0140-6736(05)67814-2
Cinotti, 1997, Effect of lisinopril on the progression of non-diabetic chronic renal failure [abstract], Nephrology Dialysis Transplantation, 12, A94
Cinotti, 2001, Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies, Nephrology Dialysis Transplantation, 16, 961, 10.1093/ndt/16.5.961
Nakao, 2004, Baseline b-adrenergic blockade-based differences for the effect of renin-angiotensin blockade for the treatment of non-diabetic hypertensive patients with chronic kidney failure: a COOPERATE-Carvedilol substudy. [abstract no: F-PO621], Journal of the American Society of Nephrology, 15, 203A
Nakao, 2006, Baseline proteinuria level and an relative nephroprotective efficacy of combination therapy of angiotensin-converting-enzyme inhibitor and angiotensin-II receptor blocker: subgroup analysis of the COOPERATE Trial [abstract no: F-PO191], Journal of the American Society of Nephrology, 17, 377A
Nakao, 2004, Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy, American Journal of Nephrology, 24, 543, 10.1159/000081953
Nakao, 2001, Combination therapy of ace inhibitor and A-II receptor antagonist more powerfully retard progression of non-diabetic renal failure than monotherapy of each drug - a multicenter, three year, double-blind, randomized trial in Japan (COOPERATE) [abstract], Nephrology Dialysis Transplantation, 16, A90
Nakao, 2003, Is small-dose combination of angiotensin receptor blocker and angiotensin-converting enzyme inhibitor still beneficial in management of CRF?: A six-by-five factorial design prospective study [abstract], Nephrology Dialysis Transplantation, 18, 134
Nakao, 2003, Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial, Lancet, 361, 117, 10.1016/S0140-6736(03)12229-5
Coratelli, 1988, Antihypertensive efficacy of enalapril maleate on impaired renal function, Kidney International - Supplement, 25, S204
Crowe, 2002, The antiproteinuric effect of losartan and its relationship to systemic blood pressure and renal haemodynamics in patients with chronic renal failure [abstract], Nephrology Dialysis Transplantation, 17, 81
Jong, 1999, Renoprotective therapy: titration against urinary protein excretion, Lancet, 354, 352, 10.1016/S0140-6736(99)90122-8
Rosa, 2001, Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study, Journal of Cardiovascular Pharmacology, 38, 482, 10.1097/00005344-200109000-00017
Vinuesa, 2006, Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade, Journal of the American Society of Nephrology, 17, S206, 10.1681/ASN.2006080916
Deuber, 2003, Improvement of proteinuria by candesartan, eprosartan, irbesartan, losartan [abstract], Nephrology Dialysis Transplantation, 18, 365
Dyadyk, 1997, ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure, Nephrology Dialysis Transplantation, 12, 945, 10.1093/ndt/12.5.945
Elung-Jensen, 2002, Renoprotective effect of high or low dosage of enalapril in progressive chronic nephropathy [abstract], Nephrology Dialysis Transplantation, 17, 239
Elung-Jensen, 2003, Blood pressure response to conventional and low-dose enalapril in chronic renal failure, British Journal of Clinical Pharmacology, 55, 139, 10.1046/j.1365-2125.2003.01764.x
Elung-Jensen, 2005, Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial, European Journal of Clinical Pharmacology, 61, 87, 10.1007/s00228-005-0893-x
Sharma, 2005, Telmisartan in patients with mild/moderate hypertension and chronic kidney disease, Clinical Nephrology, 63, 250, 10.5414/CNP63250
Faulhaber, 1997, Tolerability of valsartan and effects on renal function in treated hypertensive patients with stable renal insufficiency [abstract], Journal of the American Society of Nephrology, 8, 315A
Fleischmann, 2003, The effect of treatment with ultra high dose candesartan (64 mg) on proteinuria: Interim results of a double-blind, randomized, multi-center study [abstract], Nephrology Dialysis Transplantation, 18, 133
Fliser, 1995, Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure, Nephrology Dialysis Transplantation, 10, 643
Garg, 2005, Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study, American Journal of Nephrology, 25, 393, 10.1159/000087211
Giatras, 1997, Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, Annals of Internal Medicine, 127, 337, 10.7326/0003-4819-127-5-199709010-00001
Greenbaum, 2000, Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency, British Journal of Clinical Pharmacology, 49, 23, 10.1046/j.1365-2125.2000.00103.x
Hannedouche, 2001, Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension, Journal of the Renin-Angiotensin-Aldosterone System, 2, 246, 10.3317/jraas.2001.039
Haufe, 1994, Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril, Medizinische Klinik, 89, 416
Henriksen, 1985, Captopril in the treatment of hypertension in patients with renal insufficiency, Ugeskrift for Laeger, 147, 2451
Hogan, 2002, Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation, Pharmacoeconomics, 20, 37, 10.2165/00019053-200220010-00004
Hollenberg, 2003, Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition, Current Hypertension Reports, 5, 284
Mann, 2001, Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial, Annals of Internal Medicine, 134, 629, 10.7326/0003-4819-134-8-200104170-00007
Hou, 2006, Efficacy and safety of benazepril for advanced chronic renal insufficiency, New England Journal of Medicine, 354, 131, 10.1056/NEJMoa053107
Ihle, 1992, The effect of angiotensin converting enzyme inhibition (ACEi) on progression of chronic renal insufficiency (CRI) [abstract], Journal of the American Society of Nephrology, 3, 284
Ihle, 1996, Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial, American Journal of Kidney Diseases, 27, 489, 10.1016/S0272-6386(96)90158-4
Ishimitsu, 2005, Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases, Hypertension Research - Clinical and Experimental, 28, 865, 10.1291/hypres.28.865
Jafar, 2001, Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Annals of Internal Medicine, 135, 73, 10.7326/0003-4819-135-2-200107170-00007
Jafar, 2003, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis, Annals of Internal Medicine, 139, 244, 10.7326/0003-4819-139-4-200308190-00006
Kamper, 1990, Initial effect of enalapril on kidney function in patients with moderate to severe chronic nephropathy, Scandinavian Journal of Urology and Nephrology, 24, 69, 10.3109/00365599009180363
Kamper, 1993, Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure [abstract], Journal of the American Society of Nephrology, 4, 251
Kamper, 1990, Randomised controlled trial of enalapril in progressive chronic renal failure [abstract], Nephrology Dialysis Transplantation, 5, 672
Kamper, 1996, The influence of angiotensin-converting enzyme inhibition on renal tubular function in progressive chronic nephropathy, American Journal of Kidney Diseases, 28, 822, 10.1016/S0272-6386(96)90381-9
Kamper, 1990, Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy, Scandinavian Journal of Clinical and Laboratory Investigation, 50, 611, 10.3109/00365519009089178
Kamper, 1992, Effect of enalapril on the progression of chronic renal failure, American Journal of Hypertension, 5, 423, 10.1093/ajh/5.7.423
Kamper, 1995, Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria, Nephrology Dialysis Transplantation, 10, 1182, 10.1093/ndt/10.7.1182
Kanno, 2005, Add-on angiotensin receptor blocker in patients with chronic kidney diseases treated with angiotensin converting enzyme inhibitors [abstract], Journal of the American Society of Nephrology, 16, 105A
Kanno, 2006, Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors, Clinical Journal of the American Society of Nephrology - CJASN, 1, 730, 10.2215/CJN.01110905
Keane, 1989, Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions, Annals of Internal Medicine, 111, 503, 10.7326/0003-4819-111-6-503
Keilani, 1993, Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor, Annals of Internal Medicine, 118, 246, 10.7326/0003-4819-118-4-199302150-00002
Schlueter, 1993, Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril, American Journal of Cardiology, 72, 37H, 10.1016/0002-9149(93)91053-K
Kim HJ Han SW No more aggravation of hyperkalemia by the combined therapy of angiotensin II receptor antagonist and angiotensin converting enzyme inhibitor in renal diseases than either therapy alone [abstract no: FP.8.4] 13th Asian Colloquium in Nephrology; 2000 Nov 23-25; Bali, Indonesia 2000
Kincaid-Smith, 2002, Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria, Nephrology Dialysis Transplantation, 17, 597, 10.1093/ndt/17.4.597
Kincaid-Smith, 2004, Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure, Nephrology Dialysis Transplantation, 19, 2272, 10.1093/ndt/gfh384
Kindler, 1989, Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure, Journal of Cardiovascular Pharmacology, 13, S55, 10.1097/00005344-198900133-00014
Klein, 2003, Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure, Journal of the American Society of Nephrology, 14, 425, 10.1097/01.ASN.0000045049.72965.B7
Kshirsagar, 2000, Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials, American Journal of Kidney Diseases, 35, 695, 10.1016/S0272-6386(00)70018-7
Kunz, 2008, Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease, Annals of Internal Medicine, 148, 30, 10.7326/0003-4819-148-1-200801010-00190
Larczynski, 2007, The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract], Nephrology Dialysis Transplantation, 22, vi259
Maione, 2007, Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial, Journal of Nephrology, 20, 646
MacGregor, 2003, Effect of ACE inhibition on hemoglobin in chronic renal failure: a randomized controlled trial [abstract], Journal of the American Society of Nephrology, 14, 443A
MacKinnon, 2006, Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data, American Journal of Kidney Diseases, 48, 8, 10.1053/j.ajkd.2006.04.077
Maki, 1995, Long-term effects of antihypertensive agents on proteinuria and renal function, Archives of Internal Medicine, 155, 1073, 10.1001/archinte.1995.00430100105012
Mann, 1997, Perspectives of ace inhibition in progressive renal failure [abstract], Nephrology, 3, S39
Marcantoni, 1997, ACE inhibitors and renal insufficiency, Cardiologia, 42, 783
McFate Smith, 1984, Tolerance and safety of enalapril, British Journal of Clinical Pharmacology, 18, 249S, 10.1111/j.1365-2125.1984.tb02604.x
McFate Smith, 1984, Overall tolerance and safety of enalapril, Journal of Hypertension - Supplement, 2, S113
Mimura, 2008, Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases, Journal of Human Hypertension, 22, 38, 10.1038/sj.jhh.1002264
Minetti, 1995, Long- versus short-term effects of two different ACE inhibitors on renal haemodynamics: preliminary results from an ongoing trial, Nephrology Dialysis Transplantation, 10, 18, 10.1093/ndt/10.supp6.18
Mitchell, 1997, Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency, American Journal of Kidney Diseases, 29, 897, 10.1016/S0272-6386(97)90464-9
Muirhead, 2004, A randomised controlled trial of high dose candesartan in the treatment of proteinuric renal disease: design and baseline characteristics. [abstract], Journal of the American Society of Nephrology, 15, 357A
Herlitz, 2001, The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study, Nephrology Dialysis Transplantation, 16, 2158, 10.1093/ndt/16.11.2158
Palmer, 2008, Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease, American Journal of Nephrology, 28, 381, 10.1159/000112270
Pedersen, 1996, [Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril] [Danish], Ugeskrift for Laeger, 158, 5798
Phillips, 2007, Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials, Archives of Internal Medicine, 167, 1930, 10.1001/archinte.167.18.1930
Plum, 1998, Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension, Journal of the American Society of Nephrology, 9, 2223, 10.1681/ASN.V9122223
Plum, 1999, Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension, Nephrology Dialysis Transplantation, 14 Suppl 4, 25, 10.1093/ndt/14.suppl_4.25
Praga, 2002, Antiproteinuric effect of losartan in nondiabetic proteinuric renal diseases: A double blind, randomized clinical trial [abstract], Journal of the American Society of Nephrology, 13, 3A
Perkovic, 2007, Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study, Journal of the American Society of Nephrology, 18, 2766, 10.1681/ASN.2007020256
Anonymous, 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8
Brunetti, 2000, In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract], Journal of the American Society of Nephrology, 11, 57A
Ruggenenti, 2001, Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies, Kidney International, 59, 286, 10.1046/j.1523-1755.2001.00490.x
Ruggenenti, 1999, In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia, Journal of the American Society of Nephrology, 10, 997, 10.1681/ASN.V105997
Ruggenenti, 1998, Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy, Lancet, 352, 1252, 10.1016/S0140-6736(98)04433-X
Renke M Tylicki L Ruthkowski P Wonjnarowski K Lysiak-Szydlowska W Rutkowski B Low-dose dual blockade of the renin-angiotensin system improves tubular status in nondiabetic proteinuric patients [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 260
Hou, 2007, Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency, Journal of the American Society of Nephrology, 18, 1889, 10.1681/ASN.2006121372
Ruilope, 2000, Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease, Journal of Hypertension, 18, 89, 10.1097/00004872-200018010-00013
Rump, 1999, Angiotensin II receptor blockade in comparison to ACE inhibition in patients with chronic kidney failure, Journal fur Hypertonie, 3, 25
Sanchez, 1991, Effect of cilazapril in hypertensive patients with renal impairment, Journal of Cardiovascular Pharmacology, 17, 222, 10.1097/00005344-199102000-00007
Santoni, 1989, Tolerance and safety of perindopril, Clinical & Experimental Hypertension - Part A, Theory & Practice, 11, 605
Tokmakova, 2004, Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study, Circulation, 110, 3667, 10.1161/01.CIR.0000149806.01354.BF
Scaglione, 2005, Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial, Journal of Hypertension, 23, 657, 10.1097/01.hjh.0000160225.01845.26
Schmieder, 2004, Additional antiproteinuric effect of ultra high dose (64mg) candesartan: a double blind, randomized study [abstract], Journal of the American Society of Nephrology, 15, 119A
Schulz, 1999, A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function, Nephrology Dialysis Transplantation, 14, 27, 10.1093/ndt/14.suppl_4.27
Shiigai, 1998, Escape from the antiproteinuric effect of angiotensin-converting enzyme inhibitor in nondiabetic nephropathy [abstract], Journal of the American Society of Nephrology, 9, 80A
Shoda, 2006, A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy, Internal Medicine, 45, 193, 10.2169/internalmedicine.45.1515
Takagi N Tokita Y Takeda K Ueda S Abe Y Yabana M Effect of long-term administration of angiotensin converting enzyme inhibitors on renal function in hypertensive patients associated with renal failure [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 321A
Toto, 1996, Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria, American Journal of Kidney Diseases, 28, 832, 10.1016/S0272-6386(96)90382-0
Toto, 1998, Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group, Hypertension, 31, 684, 10.1161/01.HYP.31.2.684
Menne, 2008, Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial, Journal of Hypertension, 26, 1860, 10.1097/HJH.0b013e32830508aa
Hout, 1997, Economic evaluation of benazepril in chronic renal insufficiency, Kidney International - Supplement, 63, S159
Yildiz A Azamir M Erkoc R Kayacan SM Tukek T Gorcin B The comparison of enalapril and losartan treatment in patients with moderate chronic renal failure [abstract] 36th Congress. European Renal Association. European Dialysis and Transplantation Association; 1999 Sept 5-8; Madrid, Spain 1999 162
Yilmaz, 2007, Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan, Blood Purification, 25, 327, 10.1159/000107410
Zwettler, 1994, OACE inhibition does not interfere with acute extrarenal or renal potassium disposal in chronic renal failure, European Journal of Clinical Pharmacology, 46, 185, 10.1007/BF00192546
Dahlof, 2005, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised control trial, Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1
Centers for Disease Control and Prevention (CDC), 2007, Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004, MMWR - Morbidity and Mortality Weekly Report, 56, 161
Astor, 2001, The timing of nephrologist referral and arteriovenous access use: the CHOICE study, American Journal of Kidney Diseases, 38, 494, 10.1053/ajkd.2001.26833
Coresh, 2005, Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000, Journal of the American Society of Nephrology, 16, 180, 10.1681/ASN.2004070539
Daly, 2007, Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease, Nephrology Dialysis Transplantation, 22, ix19
Dogan, 2005, Effects of late referral to a nephrologist in patients with chronic renal failure, Nephrology, 10, 516, 10.1111/j.1440-1797.2005.00433.x
Drey, 2003, A population-based study of the incidence and outcomes of diagnosed chronic kidney disease, American Journal of Kidney Diseases, 42, 677, 10.1016/S0272-6386(03)00916-8
Giatras, 1997, Effect of angiotensin converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomised trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, Annals of Internal Medicine, 127, 337, 10.7326/0003-4819-127-5-199709010-00001
Hallan, 2006, Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey, BMJ, 333, 1047, 10.1136/bmj.39001.657755.BE
Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008 Available from www.cochrane-handbook.org
Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, New England Journal of Medicine, 342, 145, 10.1056/NEJM200001203420301
Imai, 2007, Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient, Clinical and Experimental Nephrology, 11, 156, 10.1007/s10157-007-0463-x
Jafar, 2003, Progression of chronic kidney disease: the role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition, Annals of Internal Medicine, 139, 244, 10.7326/0003-4819-139-4-200308190-00006
John, 2004, Unreferred chronic kidney disease: a longitudinal study, American Journal of Kidney Diseases, 43, 825, 10.1053/j.ajkd.2003.12.046
Khan, 2007, Economic burden of chronic kidney disease, Journal of Evaluation in Clinical Practice, 14, 422, 10.1111/j.1365-2753.2007.00883.x
Kinchen, 2002, The timing of specialist evaluation in chronic kidney disease and mortality, Annals of Internal Medicine, 137, 479, 10.7326/0003-4819-137-6-200209170-00007
Kshirsagar, 2000, Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials, American Journal of Kidney Diseases, 35, 695, 10.1016/S0272-6386(00)70018-7
2002, Kumar & Clark clinical medicine, 591-2, 825
Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated September 2008]. The Cochrane Collaboration Available from www.cochrane-handbook.org
Levey, 2003, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Annals of Internal Medicine, 139, 137, 10.7326/0003-4819-139-2-200307150-00013
Lindholm, 2002, Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 1004, 10.1016/S0140-6736(02)08090-X
Lithell, 2003, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial, Journal of Hypertension, 21, 875, 10.1097/00004872-200305000-00011
MacMahon, 2000, Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease, Journal of the American College of Cardiology, 36, 438, 10.1016/S0735-1097(00)00736-1
United States Cochrane Center Master list of journals being searched http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed February 2009)
Metcalfe, 2007, How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease, Nephrology Dialysis Transplantation, 22, ix26
National Institute for Health and Clinical Excellence Early identification and management of chronic kidney disease in adults in primary and secondary care http://guidance.nice.org.uk/CG73 (accessed August 2010) 2008
PROGRESS Collaborative Group, 2001, Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack, Lancet, 9287, 1033
Willis NS Mitchell R Higgins GY Webster AC Craig JC Cochrane Renal Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs) 2011, Issue 6. Art. No: RENAL (accessed July 2011)
Ruster, 2006, Renin-angiotensin-aldosterone system and progression of renal disease, Journal of the American Society of Nephrology, 17, 2985, 10.1681/ASN.2006040356
Teo, 2000, Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT), Circulation, 102, 1748, 10.1161/01.CIR.102.15.1748
Sharma, 2010, Does stage-3 chronic kidney disease matter? A systematic literature review, British Journal of General Practice, 60, e266, 10.3399/bjgp10X502173
Scottish Intercollegiate Guidelines Network Diagnosis and management of chronic kidney disease www.sign.ac.uk/guidelines/fulltext/103/index.html (accessed August 2010) 2008